Multibagger Return of 250% In 1 Yr: Specialty Chemical Stock In Spotlight Amid Bearish Market; Here’s Why

One of D-Street's multibagger stocks in recent times is Sudarshan Pharma Industries, after marking a 250% return in the last 1 year. Despite negative market sentiment, the multibagger pharmaceutical stock rose in early trading on Friday on the BSE. The specialty chemical firm has released its financial statements for the half-year and the fiscal year that ended on March 31, 2025, which is why the stock is probably going to be in the news in the upcoming sessions.

In the half-year ending March 31, 2025, Sudarshan Pharma Industries recorded a net profit of Rs 10.03 crore on a consolidated basis, which increased by almost 52% from Rs 6.60 crore in the half-year ended March 31, 2024. From Rs. 232 Crores in the half-year ending in March 2024 to Rs. 277 Crores in the half-year ending in March 2025, its revenue increased by 20% YoY. Additionally, the company's earnings before interest, depreciation, and taxes (EBIDT) increased from Rs 14.4 Cr to Rs 23.4 Cr, a 62 percent YoY growth.

At a revised consideration of SGD 10,000, the company successfully acquired 100% of the paid-up share capital of M/s. Sudarshan Pharma Industries Private Limited, Singapore, on February 21, 2025. Basic industrial chemicals are among the many products that Sudarshan Pharma Industries Private Limited deals in wholesale.

At a revised settlement of Rs. 1,50,00,000, the company successfully acquired 51% of M/s. Ishwari Healthcare Private Limited's paid-up equity share capital as of April 1, 2025. Ishwari Healthcare Private Limited is in the business of offering top-notch products to more effectively and efficiently meet the demands of clients throughout the world.

On a preferential basis, the company issued and handed out 9 lakh convertible warrants during the quarter under review. Within 18 months, each warrant can be converted into 10 fully paid-up equity shares of Rs. 1 each, provided that the issue price of Rs. 169.83 is paid in full. For the aforementioned issue of convertible warrants on a preferential basis, expenses of Rs. 1,35,485 have been incurred, with a total value of Rs. 1,528.47 lakhs.

APl manufacture, pharmaceutical jobwork production, and chemical and solvent trading are the company's activities in India. Only specialty chemicals are the company's primary business. Based in Mumbai, India, Sudarshan Pharma Industries Limited (SPIL) is a pharmaceutical and specialty chemicals business. Initially founded in 2008, SPIL focuses on both domestic and foreign markets and is listed on the stock exchange. The company manufactures, trades, and exports intermediates, specialty chemicals, and pharmaceutical supplies. Having worked in the chemical business for more than 25 years, SPIL has made a name for itself. The UK, Australia, Uzbekistan, and the MENA area are among the nations to which the firm dispatches its products.